-
-
Of 34 breast cancer patients with pulmonary nodules and no other evidence for metastatic disease, progression occurred in only 3 (of the 26) whose nodules were < 1 cm in diameter, compared with all 8 in whom the nodules were > 1 cm.
-
Options for CML blast phase after imatinib failure have been very limited.
-
In a post hoc analysis of patients entered on a prostate cancer clinical trial, among those receiving androgen suppression therapy, those with higher levels of comorbidity were more likely to suffer adverse consequences, and this was particularly evident for those who had lower risk for prostate cancer specific mortality.
-
A European multi-institutional trial compared outcome in terms of three-year disease-free and overall survival for patients with colon cancer who had resection either by laparoscopic approach or laparotomy.
-
In a large series of MGUS patients followed prospectively, transformation to multiple myeloma or other hematological malignancy, although present, was at a rate considerably lower than expected, based upon reports from retrospective series. Nevertheless, overall survival for MGUS patients was significantly less than that for the general population.
-
-
Drug combinations for hypertension; tenecteplase for out-of-hospital cardiac arrest; CAM most commonly used for back, neck, and arthritis pain; FDA Actions.
-
The risk of recurrent venous thromboembolism (VTE) during extended anticoagulant therapy for thrombophilia remains poorly defined. Investigators analyzed 661 patients with idiopathic VTE who had been randomized to extended prophylaxis after three months of initial anticoagulation using either low intensity (INR 1.5-1.9) or standard intensity (INR 2.0-3.0) anticoagulation.
-
The role of bisphosphonates in the treatment and prevention of bone metastases remains incompletely characterized. In the current report, Diel et al detail long-term survival data on patients with known microscopic bone disease more than eight years after adjuvant treatment with clodronate.
